Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Bu

Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowne

4D Molecular Therapeutics remains a 'Buy' as its gene therapy 4D-150 advances in phase 3 trials for

B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a B

EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT

U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; seve

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) insider Scott Bizily sold 1,635 sha

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) have earned an average re

4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare C

4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conf

Analysts upgraded Coinbase, 4D Molecular Therapeutics, Affirm, Chime Financial and Bullish, raising

Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neu

EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)

Deutsche Bank AG acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) in the secon

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report)'s share price reached a new 52-week

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.04 per share in line wit

Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027  4D-150 4

B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDA

Subscribers to  Chart of the Week  received this commentary on Sunday, July 26.

4D Molecular Therapeutics, Inc. maintains a Buy rating, driven by advancing 4D-150 gene therapy for

4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDM

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with c

EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 ove

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDM

RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperfo

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly earnings of $0.43 per share which beat th

FDMT: 86% | 4DMT Presents Interim Data From Randomized Phase 2 PRISM Clinical Trial Of Intravitreal

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expe

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday afte

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.

  On Friday, 422 stocks made new 52-week lows.

  On Tuesday, 540 companies set new 52-week lows.

  On Tuesday, 123 stocks made new 52-week lows.

  During Wednesday's trading, 435 companies set new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.